HCV Infection: Clinical Trials

18 completed, 1 withdrawn. 19 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	19	Completed 18, Withdrawn 1
Phase 2	1	Withdrawn 1

Follow HCV Infection: new trials by email Literature Review of HCV Infection trials Research Report on HCV Infection

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic	Phase 1 / Phase 2	Withdrawn	Atea Pharmaceuticals, Inc.		2021-10-01	2022-06-08
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection GLS-6150 - HCV Infection	Phase 1	Completed	GeneOne Life Science, Inc.	32	2018-09-04	2020-05-27
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection SH229, Placebos - HCV Infection	Phase 1	Completed	Nanjing Sanhome Pharmaceutical, Co., Ltd.	30	2018-07-07	2018-08-28
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol - HCV Infection	Phase 1	Completed	Gilead Sciences	15	2015-10-29	2020-09-02
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment Voxilaprevir - HCV Infection	Phase 1	Completed	Gilead Sciences	20	2015-05-05	2020-03-20
Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment Voxilaprevir - HCV Infection	Phase 1	Completed	Gilead Sciences	33	2015-03-24	2020-04-09
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C GS-5885, Placebo - HCV Infection	Phase 1	Completed	Gilead Sciences	71	2010-08-01	2013-01-21
Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects ABT-267, Placebo, Blood Sample Collection - HCV Infection	Phase 1	Completed	Abbott	137	2010-08-01	2012-01-24
A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection Naringenin - Hepatitis C Virus, HCV Infection	Phase 1	Completed	Massachusetts General Hospital	7	2009-06-01	2015-09-23
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir ABT-450, ritonavir, Placebo for ABT-450 - HCV Infection	Phase 1	Completed	Abbott	38	2009-06-01	2010-10-13
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir ABT-450, ritonavir - HCV Infection	Phase 1	Completed	Abbott	8	2009-05-01	2010-10-13
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet ABT-333, Placebo - HCV Infection	Phase 1	Completed	Abbott	24	2009-05-01	2010-10-13
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C ABT-072, ketoconazole, Placebo - HCV Infection	Phase 1	Completed	Abbott	32	2009-04-01	2010-10-21
Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers ABT-333 Tablet, Placebo, ABT-333 Capsule - HCV Infection	Phase 1	Completed	Abbott	34	2009-04-01	2010-10-13
Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1 ABT-450, ritonavir, placebo for ABT-450 - HCV Infection	Phase 1	Completed	AbbVie	87	2009-02-01	2017-11-20
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333 ABT-333, ketoconazole, placebo - HCV Infection	Phase 1	Completed	Abbott	45	2008-10-01	2010-10-13
Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects ABT-333, Placebo - HCV Infection	Phase 1	Completed	AbbVie	133	2008-06-01	2017-11-21
Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) ANA773, Placebo - HCV Infection	Phase 1	Completed	Hoffmann-La Roche	75	2008-06-01	2012-11-14
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection VCH 916, Placebo - HCV Infection	Phase 1	Completed	Vertex Pharmaceuticals Incorporated	42	2007-11-01	2014-04-04

Narrower conditions

Hepatitis C (19)  ·  Hepatitis C, Chronic (1)

Broader conditions

Blood-Borne Infections (19)  ·  Communicable Diseases (19)  ·  Digestive System Diseases (19)  ·  Flaviviridae Infections (19)  ·  Hepatitis (19)  ·  Hepatitis, Viral, Human (19)  ·  Infections (19)  ·  Liver Diseases (19)  ·  RNA Virus Infections (19)  ·  Virus Diseases (19)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Hepatitis, Chronic (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

dasabuvir (4)  ·  Ritonavir (3)  ·  paritaprevir (3)  ·  voxilaprevir (3)  ·  Ketoconazole (2)  ·  ABT-072 (1)  ·  AT-511 (1)  ·  Moxifloxacin (1)  ·  grapefruit seed extract (1)  ·  ledipasvir (1)  ·  naringenin (1)  ·  ombitasvir (1)  ·  sofosbuvir-velpatasvir drug combination (1)

Sponsors

Abbott (7)  ·  Gilead Sciences (4)  ·  AbbVie (2)  ·  Atea Pharmaceuticals, Inc. (1)  ·  GeneOne Life Science, Inc. (1)  ·  Hoffmann-La Roche (1)  ·  Massachusetts General Hospital (1)  ·  Nanjing Sanhome Pharmaceutical, Co., Ltd. (1)  ·  Vertex Pharmaceuticals Incorporated (1)

Countries

United States (13)  ·  New Zealand (3)  ·  Germany (2)  ·  Belgium (1)  ·  Canada (1)  ·  China (1)  ·  Netherlands (1)  ·  Puerto Rico (1)  ·  South Korea (1)

Top investigators

Daniel Cohen, MD (3)  ·  Isabelle A Gaultier, M.S., IBMH (2)  ·  Adebayo A Lawal, MD (1)  ·  Andrew Campbell, MD (1)  ·  Arthur Y Kim, M.D. (1)  ·  Diana Brainard, MD (1)  ·  John McHutchison, MD (1)  ·  Xiao-Jian Zhou (1)  ·  Yanhua Ding, MD (1)

Results publications

PMID 23877691, PMID 25451055, PMID 26597291, PMID 26710243

NIH funding

2015 (2), 2019 (1)